BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 33096160)

  • 1. Discovery of SARxxxx92, a pan-PIM kinase inhibitor, efficacious in a KG1 tumor model.
    Barberis C; Erdman P; Czekaj M; Fire L; Pribish J; Tserlin E; Maniar S; Batchelor JD; Liu J; Patel VF; Hebert A; Levit M; Wang A; Sun F; Huang SA
    Bioorg Med Chem Lett; 2020 Dec; 30(23):127625. PubMed ID: 33096160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of N-substituted 7-azaindoles as Pan-PIM kinases inhibitors - Lead optimization - Part III.
    Barberis C; Pribish J; Tserlin E; Gross A; Czekaj M; Barragué M; Erdman P; Maniar S; Jiang J; Fire L; Patel V; Hebert A; Levit M; Wang A; Sun F; Huang SA
    Bioorg Med Chem Lett; 2019 Feb; 29(3):491-495. PubMed ID: 30553737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of N-substituted 7-azaindoles as Pan-PIM kinase inhibitors - Lead series identification - Part II.
    Barberis C; Moorcroft N; Pribish J; Tserlin E; Gross A; Czekaj M; Barrague M; Erdman P; Majid T; Batchelor J; Levit M; Hebert A; Shen L; Moreno-Mazza S; Wang A
    Bioorg Med Chem Lett; 2017 Oct; 27(20):4735-4740. PubMed ID: 28927793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and evaluation of 3,5-disubstituted indole derivatives as Pim kinase inhibitors.
    More KN; Hong VS; Lee A; Park J; Kim S; Lee J
    Bioorg Med Chem Lett; 2018 Aug; 28(14):2513-2517. PubMed ID: 29871845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of N-substituted 7-azaindoles as PIM1 kinase inhibitors - Part I.
    Barberis C; Moorcroft N; Arendt C; Levit M; Moreno-Mazza S; Batchelor J; Mechin I; Majid T
    Bioorg Med Chem Lett; 2017 Oct; 27(20):4730-4734. PubMed ID: 28947155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma.
    Wang X; Blackaby W; Allen V; Chan GKY; Chang JH; Chiang PC; Diène C; Drummond J; Do S; Fan E; Harstad EB; Hodges A; Hu H; Jia W; Kofie W; Kolesnikov A; Lyssikatos JP; Ly J; Matteucci M; Moffat JG; Munugalavadla V; Murray J; Nash D; Noland CL; Del Rosario G; Ross L; Rouse C; Sharpe A; Slaga D; Sun M; Tsui V; Wallweber H; Yu SF; Ebens AJ
    J Med Chem; 2019 Feb; 62(4):2140-2153. PubMed ID: 30715878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational evolution of a novel type of potent and selective proviral integration site in Moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound.
    Nakano H; Saito N; Parker L; Tada Y; Abe M; Tsuganezawa K; Yokoyama S; Tanaka A; Kojima H; Okabe T; Nagano T
    J Med Chem; 2012 Jun; 55(11):5151-64. PubMed ID: 22540945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pim kinase inhibitory and antiproliferative activity of a novel series of meridianin C derivatives.
    More KN; Jang HW; Hong VS; Lee J
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2424-8. PubMed ID: 24775304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors.
    Pettus LH; Andrews KL; Booker SK; Chen J; Cee VJ; Chavez F; Chen Y; Eastwood H; Guerrero N; Herberich B; Hickman D; Lanman BA; Laszlo J; Lee MR; Lipford JR; Mattson B; Mohr C; Nguyen Y; Norman MH; Powers D; Reed AB; Rex K; Sastri C; Tamayo N; Wang P; Winston JT; Wu B; Wu T; Wurz RP; Xu Y; Zhou Y; Tasker AS; Wang HL
    J Med Chem; 2016 Jul; 59(13):6407-30. PubMed ID: 27285051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors.
    Martínez-González S; Rodríguez-Arístegui S; Gómez de la Oliva CA; Hernández AI; González Cantalapiedra E; Varela C; García AB; Rabal O; Oyarzabal J; Bischoff JR; Klett J; Albarrán MI; Cebriá A; Ajenjo N; García-Serelde B; Gómez-Casero E; Cuadrado-Urbano M; Cebrián D; Blanco-Aparicio C; Pastor J
    Eur J Med Chem; 2019 Apr; 168():87-109. PubMed ID: 30802730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-Thioxothiazolidin-4-one Analogs as Pan-PIM Kinase Inhibitors.
    Yun Y; Hong VS; Jeong S; Choo H; Kim S; Lee J
    Chem Pharm Bull (Tokyo); 2021; 69(9):854-861. PubMed ID: 34470949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors.
    Akué-Gédu R; Rossignol E; Azzaro S; Knapp S; Filippakopoulos P; Bullock AN; Bain J; Cohen P; Prudhomme M; Anizon F; Moreau P
    J Med Chem; 2009 Oct; 52(20):6369-81. PubMed ID: 19788246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological activities of 4-substituted pyrrolo[2,3-a]carbazole Pim kinase inhibitors.
    Giraud F; Akué-Gédu R; Nauton L; Candelon N; Debiton E; Théry V; Anizon F; Moreau P
    Eur J Med Chem; 2012 Oct; 56():225-36. PubMed ID: 22982527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 3,5-substituted 6-azaindazoles as potent pan-Pim inhibitors.
    Hu H; Wang X; Chan GK; Chang JH; Do S; Drummond J; Ebens A; Lee W; Ly J; Lyssikatos JP; Murray J; Moffat JG; Chao Q; Tsui V; Wallweber H; Kolesnikov A
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5258-64. PubMed ID: 26459208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
    Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
    Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-substituted azaindoles as potent inhibitors of Cdc7 kinase.
    Bryan MC; Falsey JR; Frohn M; Reichelt A; Yao G; Bartberger MD; Bailis JM; Zalameda L; Miguel TS; Doherty EM; Allen JG
    Bioorg Med Chem Lett; 2013 Apr; 23(7):2056-60. PubMed ID: 23481650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of substituted pyrido[3,2-d]-1,2,3-triazines as potential Pim-1 inhibitors.
    Fan YB; Li K; Huang M; Cao Y; Li Y; Jin SY; Liu WB; Wen JC; Liu D; Zhao LX
    Bioorg Med Chem Lett; 2016 Feb; 26(4):1224-8. PubMed ID: 26804231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The design, synthesis, and biological evaluation of PIM kinase inhibitors.
    Tsuhako AL; Brown DS; Koltun ES; Aay N; Arcalas A; Chan V; Du H; Engst S; Franzini M; Galan A; Huang P; Johnston S; Kane B; Kim MH; Laird AD; Lin R; Mock L; Ngan I; Pack M; Stott G; Stout TJ; Yu P; Zaharia C; Zhang W; Zhou P; Nuss JM; Kearney PC; Xu W
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3732-8. PubMed ID: 22542012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of ( R)-8-(6-Methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4- b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)quinazolin-4(3 H)-one, a Potent and Selective Pim-1/2 Kinase Inhibitor for Hematological Malignancies.
    Wang HL; Andrews KL; Booker SK; Canon J; Cee VJ; Chavez F; Chen Y; Eastwood H; Guerrero N; Herberich B; Hickman D; Lanman BA; Laszlo J; Lee MR; Lipford JR; Mattson B; Mohr C; Nguyen Y; Norman MH; Pettus LH; Powers D; Reed AB; Rex K; Sastri C; Tamayo N; Wang P; Winston JT; Wu B; Wu Q; Wu T; Wurz RP; Xu Y; Zhou Y; Tasker AS
    J Med Chem; 2019 Feb; 62(3):1523-1540. PubMed ID: 30624936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combination strategy to inhibit Pim-1: synergism between noncompetitive and ATP-competitive inhibitors.
    Mori M; Tintori C; Christopher RS; Radi M; Schenone S; Musumeci F; Brullo C; Sanità P; Delle Monache S; Angelucci A; Kissova M; Crespan E; Maga G; Botta M
    ChemMedChem; 2013 Mar; 8(3):484-96. PubMed ID: 23436791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.